What’s new

• The company's CDMO pipeline holds over 100 opportunities with an estimated peak revenue of ₹3,500 cr.
• The Bharuch CDMO plant has been successfully commissioned.
• Contractual 'make-whole' provisions protect the company from financial stress at a major agro-CDMO customer.

Why it matters

The transcript adds a concrete number to a growth story, putting a scale on the CDMO push. The make-whole provision is a specific contractual hedge against a known risk, limiting downside on a key contract.

What we’re watching

• Conversion rate of the 100+ pipeline opportunities into firm contracts.
• Margin recovery in the acetyls segment.
• Execution progress at the new Bharuch plant.

The full read

Jubilant Ingrevia's Q4/FY26 earnings call transcript puts a number on its CDMO push. Management disclosed a pipeline of over 100 CDMO opportunities with an estimated peak revenue of ₹3,500 crore. The call also confirmed the successful commissioning of its Bharuch CDMO plant and detailed contractual 'make-whole' provisions that shield the company from financial stress at a major agro-CDMO customer. The document is fundamentally backward-looking, providing qualitative detail on the results already reported. The key new figure is the ₹3,500 crore pipeline estimate, which gives a concrete scale to the company's contract-development business.

Primary source: BSE · NSE

What’s new

• The client for the $300M agro contract is in financial distress.
• Management expects at least 20% YoY EBITDA growth for FY27.
• Capex for the current year is set at ₹400-500 crore.

Why it matters

The $300M contract is the primary driver of the company's growth. A distressed client introduces execution risk that threatens the expected volume ramp-up.

What we’re watching

• Updates on the client's financial health and order flow.
• Evidence of sequential revenue and profit recovery starting in Q1.
• Progress on the ₹400-500 crore capex program.

The full read

Jubilant Ingrevia faces a test for its $300 million agro CDMO contract. Management disclosed that the client is experiencing financial difficulties, casting doubt on the anticipated volume ramp-up.

Contractual make-whole provisions offer protection.

Despite this, management remains confident in its broader performance, guiding for at least 20% year-on-year EBITDA growth for FY27. The company expects sequential revenue and profit recovery to begin in the first quarter. Meanwhile, the firm continues its investment cycle with a planned capex of ₹400-500 crore for the year. Management also noted that its Pinnacle strategy has delivered 33% higher EBITDA over the last two years, even in the face of price deflation. The open question is whether the client's financial situation will force a revision of the contract's volume expectations.

Primary source: BSE · NSE

What’s new

• Q4 revenue climbed 12% YoY to ₹1,179 cr on 10% volume growth and improved pricing.
• EBITDA grew 11% to ₹172 cr; PAT rose 17% to ₹86 cr.
• Commissioned a new agro CDMO facility and avoided production losses from Middle East supply disruptions.

Why it matters

A 14-quarter profit high is a clear signal that the volume recovery in specialty chemicals and nutrition is real, not just guidance. The new agro CDMO facility also adds capacity just as the company expects sequential growth to continue.

What we’re watching

• Q1 FY27 execution against the guidance for sequential revenue and EBITDA growth.
• Momentum in the acetyls segment following the demand recovery noted by management.
• Performance of the newly commissioned agro CDMO facility.

The full read

Jubilant Ingrevia's Q4 numbers confirm a genuine recovery. Revenue of ₹1,179 crore was up 12% year-on-year, fueled by 10% volume growth and better pricing. That flow-through reached the bottom line, where net profit of ₹86 crore marked the company's best quarter in 14 quarters. The operation was also resilient: it dodged Middle East supply disruptions without downtime and added a new agro CDMO facility. Management's guidance for sequential growth into FY27 is optimistic, but it rests on a tangible base. The acetyls business is recovering, and the specialty chemicals and nutrition segments are already carrying momentum. The question is execution, not demand.

Primary source: BSE · NSE

What’s new

• Q4 consolidated revenue rose 12% year-on-year to ₹1,179 cr, driven by 10% volume growth across all segments.
• EBITDA increased 11% to ₹172 cr; net profit grew 17% to ₹86 cr.
• The company guided for sequential revenue and EBITDA growth from Q1 FY27, led by specialty chemicals and nutrition.

Why it matters

This is the strongest quarter the specialty chemicals firm has posted in over three years. The guidance for continued sequential expansion is an explicit signal from management that the momentum is not a one-quarter event. The volume-driven growth, in particular, suggests underlying demand is holding, not just pricing power.

What we’re watching

• The revenue ramp from the new agro CDMO facility in Q1 FY27.
• Sustainability of the 10% volume growth trend amid global supply-chain noise.
• Management's ability to hold the 15% EBITDA margin as costs fluctuate.

The full read

Jubilant Ingrevia just delivered its strongest quarter in 14. Revenue hit ₹1,179 crore, up 12% year-on-year, and it wasn't price doing the work. Volume rose 10% across every segment. EBITDA climbed to ₹172 crore, net profit jumped 17% to ₹86 crore, and the board is paying out ₹2.50 a share as a final dividend. The specialty chemicals maker also navigated Middle East supply snags without halting production and began dispatching from its new agro CDMO plant. Now for the forward view: management is calling for sequential growth in both sales and profit to start the next financial year. That is a specific, confident forecast for a cyclical industry. The open question is whether the new CDMO facility can scale fast enough to underpin that call.

Primary source: BSE · NSE

What’s new

• FY26 consolidated profit rose 10.6% to ₹278 crore.
• Revenue from operations increased 5% to ₹4,388 crore.
• Board recommends a ₹2.5 per share final dividend.

Why it matters

This is a standard annual filing that met market expectations. The growth is steady, not accelerating. The ₹13 crore charge for new labour codes is the only non-operational blip, and it is minor in the context of a ₹278 crore profit.

What we’re watching

• Demand commentary for specialty chemicals in coming quarters.
• Margin performance post the one-time charge.
• Any shift in capital allocation or expansion plans.

The full read

Jubilant Ingrevia delivered what it was expected to deliver. Full-year consolidated profit rose 10.6% to ₹278 crore. Revenue grew 5% to ₹4,388 crore. The numbers are steady. Unremarkable. A ₹13 crore one-time charge for new labour codes is the only non-operational item, and it barely moves the needle on a ₹278 crore bottom line. The board also proposed a ₹2.5 per share final dividend. For a mid-cap specialty chemicals company, this is business as usual. There is nothing here to force a re-rating or a model change.

Primary source: BSE · NSE